194 related articles for article (PubMed ID: 16541479)
21. Exercise therapy for people with rheumatoid arthritis and osteoarthritis.
Kettunen JA; Kujala UM
Scand J Med Sci Sports; 2004 Jun; 14(3):138-42. PubMed ID: 15144352
[TBL] [Abstract][Full Text] [Related]
22. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
Lindgren P; Geborek P; Kobelt G
Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
[TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
24. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs.
Woo J; Lau E; Lau CS; Lee P; Zhang J; Kwok T; Chan C; Chiu P; Chan KM; Chan A; Lam D
Arthritis Rheum; 2003 Aug; 49(4):526-34. PubMed ID: 12910559
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of two self-care interventions to reduce disability associated with back pain.
Strong LL; Von Korff M; Saunders K; Moore JE
Spine (Phila Pa 1976); 2006 Jul; 31(15):1639-45. PubMed ID: 16816756
[TBL] [Abstract][Full Text] [Related]
26. The economics of treatment in early rheumatoid arthritis.
Bansback N; Marra CA; Finckh A; Anis A
Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
[TBL] [Abstract][Full Text] [Related]
27. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
[TBL] [Abstract][Full Text] [Related]
28. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
Hoerger TJ
Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
[TBL] [Abstract][Full Text] [Related]
29. Shyness programme: longer term benefits, cost-effectiveness, and acceptability.
Titov N; Andrews G; Johnston L; Schwencke G; Choi I
Aust N Z J Psychiatry; 2009 Jan; 43(1):36-44. PubMed ID: 19085526
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
[TBL] [Abstract][Full Text] [Related]
31. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
32. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.
Kobelt G; Jönsson B
Eur J Health Econ; 2008 Jan; 8 Suppl 2():95-106. PubMed ID: 18157559
[TBL] [Abstract][Full Text] [Related]
33. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya.
Goodman CA; Mutemi WM; Baya EK; Willetts A; Marsh V
Health Policy Plan; 2006 Jul; 21(4):275-88. PubMed ID: 16682433
[TBL] [Abstract][Full Text] [Related]
35. Estimating the costs and health benefits of water and sanitation improvements at global level.
Haller L; Hutton G; Bartram J
J Water Health; 2007 Dec; 5(4):467-80. PubMed ID: 17878561
[TBL] [Abstract][Full Text] [Related]
36. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
37. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
[TBL] [Abstract][Full Text] [Related]
38. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
Osiri M; Maetzel A; Tugwell P
J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Olliaro P; Darley S; Laxminarayan R; Sundar S
Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
[TBL] [Abstract][Full Text] [Related]
40. The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD.
Am J Manag Care; 1999 Sep; 5(14 Suppl):S852-9; discussion S866-9. PubMed ID: 10621071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
